Altered Folate Homeostasis in Children with Down Syndrome: A Potential Basis for Enhanced Methotrexate Toxicity.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 32111377.
- Also identified by DOI 10.1016/j.jpeds.2020.01.032 and PMC identifier 7247922.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Methotrexate is used to treat autoimmune and oncologic diseases in children with Down syndrome. However, increased methotrexate-related toxicity is reported in this population. We evaluated differences in the concentrations and distribution of erythrocyte folates in children with Down syndrome as a potential basis for this enhanced toxicity.
Medical subject headings
- Down Syndrome
- Folic Acid
- Homeostasis